Literature DB >> 9333178

Restriction fragment length polymorphism analysis and random amplified polymorphic DNA analysis of Campylobacter jejuni strains isolated from patients with Guillain-Barré syndrome.

S Fujimoto1, B M Allos, N Misawa, C M Patton, M J Blaser.   

Abstract

Campylobacter jejuni serotype O19 strains associated with the Guillain-Barré syndrome (GBS) and other strains were examined by restriction fragment length polymorphism (RFLP) analysis of polymerase chain reaction products of the flaA genes and by random amplified polymorphic DNA (RAPD) analysis. RFLP analysis showed that regardless of LIO serotype, geographic origins, or association with GBS, the O19 isolates shared an identical digestion pattern by each of four restriction endonucleases, DdeI, MboI, MseI, and AluI. In contrast, among C. jejuni O1 or O2 strains, RFLP patterns were different even among strains of the same LIO serotype. The results of the RAPD analysis were consistent with the flaA RFLP data. These data indicate that all of the O19 strains that were tested were closely related to one another whether they were or were not associated with GBS.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9333178     DOI: 10.1086/516522

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  22 in total

1.  Genetic characterization of Campylobacter jejuni O:41 isolates in relation with Guillain-Barré syndrome.

Authors:  T M Wassenaar; B N Fry; A J Lastovica; J A Wagenaar; P J Coloe; B Duim
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

2.  Heat-labile serotyping of two Campylobacter jejuni strains isolated from patients with Guillain-Barré syndrome and belonging to serotype O19 (Penner)

Authors:  R S Tsang; P Frosk; W M Johnson
Journal:  J Clin Microbiol       Date:  2000-05       Impact factor: 5.948

Review 3.  Genotyping of Campylobacter spp.

Authors:  T M Wassenaar; D G Newell
Journal:  Appl Environ Microbiol       Date:  2000-01       Impact factor: 4.792

4.  Molecular characterization of Campylobacter jejuni from patients with Guillain-Barré and Miller Fisher syndromes.

Authors:  H P Endtz; C W Ang; N van Den Braak; B Duim; A Rigter; L J Price; D L Woodward; F G Rodgers; W M Johnson; J A Wagenaar; B C Jacobs; H A Verbrugh; A van Belkum
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

5.  Allelic diversity and recombination in Campylobacter jejuni.

Authors:  S Suerbaum; M Lohrengel; A Sonnevend; F Ruberg; M Kist
Journal:  J Bacteriol       Date:  2001-04       Impact factor: 3.490

6.  New Identification of Three or More Campylobacter Species on the Basis of a Degenerate PCR-RFLP Method Targeting gyrB Gene.

Authors:  Hiroyuki Fukuda; Fumiko Kojima; Shuji Fujimoto
Journal:  Curr Microbiol       Date:  2017-07-17       Impact factor: 2.188

7.  Flagella as a potential marker for Campylobacter jejuni strains associated with Guillain-Barré syndrome.

Authors:  R S Tsang; G Figueroa; L Bryden; L Ng
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

8.  Restriction fragment length polymorphism analysis using random chromosomal gene probes for epidemiological analysis of Campylobacter jejuni infections.

Authors:  S Fujimoto; K Umene; M Saito; K Horikawa; M J Blaser
Journal:  J Clin Microbiol       Date:  2000-04       Impact factor: 5.948

9.  Development and application of a new scheme for typing Campylobacter jejuni and Campylobacter coli by PCR-based restriction fragment length polymorphism analysis.

Authors:  Feng Shi; Yuen Yuen Chen; Trudy M Wassenaar; Walter H Woods; Peter J Coloe; Benjamin N Fry
Journal:  J Clin Microbiol       Date:  2002-05       Impact factor: 5.948

10.  Comparative genotyping of Campylobacter jejuni strains from patients with Guillain-Barré syndrome in Bangladesh.

Authors:  Zhahirul Islam; Alex van Belkum; Jaap A Wagenaar; Alison J Cody; Albert G de Boer; Helen Tabor; Bart C Jacobs; Kaisar A Talukder; Hubert P Endtz
Journal:  PLoS One       Date:  2009-09-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.